title: Update on clinical radiobiology.
abstract: Radiation therapy is an important local cytotoxic modality for cancer treatment whose aim is to control the disease while minimising damage to normal tissue. The combination of different treatment modalities offers a more effective cure and reduction in normal tissue toxicity. However, the differences in genetic profiles can cause diverse treatment outcomes. Multidisciplinary research, where technologies and knowledge from different areas are integrated, is necessary to design the optimal regimen for individualised cancer treatment. This paper offers an overview of some new cancer treatment strategies; the impact of molecular imaging on radiation oncology; and a computer simulation model to optimise treatment planning based on patient information. It briefly discusses molecular targeted therapy, tumour microenvironment and bioreductive agents, and evidence for making individualised medicine a reality. Using DNA microarrays and proteomic technologies, information on defined molecular targets and genetic profiling for individual patients can be obtained and new algorithms for radiation oncology-related diagnosis, treatment response and prognosis can be developed.
authors: Division of Therapeutic Radiology and Oncology, Faculty of Medicine, ChiangMai University, Chiang Mai, Thailand.
authors: N
authors: N
authors: Chawapun
references: Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1059-63
references: 15057490
references: Cell. 1996 Aug 9;86(3):353-64
references: 8756718
references: Radiother Oncol. 2004 Sep;72(3):257-66
references: 15450723
references: Clin Cancer Res. 2003 Dec 15;9(17):6316-25
references: 14695130
references: Strahlenther Onkol. 2005 Aug;181(8):483-99
references: 16044216
references: Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):655-66
references: 16199306
references: J Theor Biol. 2004 Sep 7;230(1):1-20
references: 15275995
references: Int J Cancer. 2003 Dec 20;107(6):1030-7
references: 14601066
references: Int J Radiat Biol. 2000 May;76(5):589-605
references: 10866281
references: Br J Cancer. 2003 Aug 4;89(3):585-92
references: 12888834
references: Radiother Oncol. 1998 Feb;46(2):135-46
references: 9510041
references: Clin Cancer Res. 2004 Oct 1;10(19):6476-86
references: 15475435
references: Oncologist. 2003;8(3):293-4
references: 12773751
references: N Engl J Med. 2005 Jun 16;352(24):2487-98
references: 15958804
references: Oncologist. 2004;9 Suppl 5:4-9
references: 15591417
references: Cancer Res. 2004 Jul 15;64(14):4931-41
references: 15256466
references: Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1264-73
references: 16029781
references: Comput Biol Med. 2006 May;36(5):448-64
references: 15916755
references: Cancer Imaging. 2005 Jun 21;5:51-7
references: 16154820
references: Transfus Clin Biol. 2005 Feb;12(1):5-10
references: 15814285
references: Expert Opin Investig Drugs. 1998 Jun;7(6):905-28
references: 15992006
references: Hosp Pract (1995). 1999 Jan 15;34(1):63-8, 77-9, 83-4
references: 9931577
references: Crit Rev Oncol Hematol. 2005 Mar;53(3):179-92
references: 15718144
references: Radiat Res. 2003 Apr;159(4):439-52
references: 12643788
references: Radiol Clin North Am. 2005 Jan;43(1):189-204
references: 15693656
references: Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):941-9
references: 14967454
references: J Cell Physiol. 2003 Dec;197(3):312-25
references: 14566961
references: Conf Proc IEEE Eng Med Biol Soc. 2004;2004:3035-8
references: 17270918